Brain

LandingAI Launches Agentic Document Extraction for Unlocking Insights from Complex Documents

Transforming Enterprises Complex Document Workflows and Understanding with Agentic Vision Technologies PALO ALTO, Calif., May 28, 2025 /PRNewswire/ -- LandingAI,…

7 months ago

Immunotherapeutic Targets for Recurrent Medulloblastoma Receives $85K Grant from Brain Cancer Canada

TORONTO, May 28, 2025 (GLOBE NEWSWIRE) -- Brain Cancer Canada is proud to award $85,000 to a groundbreaking research project…

7 months ago

Achieve Life Sciences to Present at the Jefferies Global Healthcare Conference

SEATTLE and VANCOUVER, British Columbia, May 28, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage specialty…

7 months ago

DentScribe CoPilot Launches AI That Turns SOAP Notes into a Real-Time Dental Care Checklist, Now Live for Every Practice

SUNNYVALE, Calif., May 28, 2025 /PRNewswire/ -- Imagine starting every dental appointment with an AI-generated checklist built just for your…

7 months ago

CEFALY Technology Introduces CEFALY@Work: A Workplace Wellness Initiative for Employees With Migraine

DARIEN, Conn., May 27, 2025 /PRNewswire/ -- Medical device maker CEFALY Technology today announced the launch of CEFALY@Work, a new offering…

7 months ago

Vaccinex to Report Promising New Clinical Results of Neoadjuvant Treatment with Pepinemab to Enhance Immunotherapy in Patients with Head and Neck Cancer at ASCO Annual Meeting

Neoadjuvant treatment with pepinemab appears to induce abundant, mature lymphoid structures that correlate with improved pathologic response.ROCHESTER, N.Y., May 27,…

7 months ago

Masimo to Present in the Jefferies Global Healthcare Conference

IRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) today announced that its management will participate in the Jefferies Global Healthcare Conference on Wednesday,…

7 months ago

NeuroPace Announces Preliminary Results from One-Year Data in NAUTILUS Study

-- NeuroPace has completed the primary endpoint analysis of the one-year data from the first and only clinical study to…

7 months ago

ORIC® Pharmaceuticals to Present Initial Data from Phase 1b Trial of ORIC-944 in Combination with Androgen Receptor Inhibitors in Patients with mCRPC

Conference Call and Webcast on Wednesday, May 28, 2025, at 4:30 p.m. ETSOUTH SAN FRANCISCO, Calif. and SAN DIEGO, May…

7 months ago